These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study. Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354 [TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study. Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532 [TBL] [Abstract][Full Text] [Related]
32. Issues in the pharmacological treatment of obsessive-compulsive disorder. Math SB; Janardhan Reddy YC Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795 [TBL] [Abstract][Full Text] [Related]
33. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652 [TBL] [Abstract][Full Text] [Related]
34. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523 [TBL] [Abstract][Full Text] [Related]
35. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Uzun O; Ozdemir B Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402 [TBL] [Abstract][Full Text] [Related]
36. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. Zajecka J; Tracy KA; Mitchell S J Clin Psychiatry; 1997 Jul; 58(7):291-7. PubMed ID: 9269249 [TBL] [Abstract][Full Text] [Related]
37. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Metin O; Yazici K; Tot S; Yazici AE Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825 [TBL] [Abstract][Full Text] [Related]
38. Trichotillomania in youth: a retrospective case series. Mancini C; Van Ameringen M; Patterson B; Simpson W; Truong C Depress Anxiety; 2009; 26(7):661-5. PubMed ID: 19496078 [TBL] [Abstract][Full Text] [Related]
39. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Denys D; de Geus F; van Megen HJ; Westenberg HG J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587 [TBL] [Abstract][Full Text] [Related]